Clinical trials for Multiple myeloma
62 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Multiple myeloma
#NCT04973605
#2023-507751-30-00
Partie 1 et Partie 2 cohortes 1 et 2
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required genetic anomalies
t(11;14)
Required number of previous lines of therapy
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
BeOne Medecines
Phase 1 / Phase 2
Multiple myeloma
#NCT06106945
#2023-508590-89-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
2 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Multiple myeloma
#NCT05583617
#2021-005918-34
Sous-étude 2 (Haut risque, post autogreffe)
Required histologic types
Symptomatic multiple myeloma
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Autologous stem cell transplant
Required IMWG cytogenetic prognoses
High risk
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Hoffmann-La Roche
Phase 1 / Phase 2
Multiple myeloma
#NCT05583617
#2021-005918-34
Sous étude 4 (exposition aux 3 classes thérapeutiques)
Required histologic types
Symptomatic multiple myeloma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
3 recruiting sites
Hoffmann-La Roche
Phase 1
Multiple myeloma
#NCT05137054
#2020-004638-39
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Autologous stem cell transplant
Allogeneic stem cell transplant
9 recruiting sites
Regeneron Pharmaceuticals
Phase 1
Multiple myeloma
#NCT05651932
#2022-500801-41-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
K36 Therapeutics, Inc.
Phase 1
Multiple myeloma
#NCT05652335
#2022-001465-12
Cohorte myélome multiple récidivant ou réfractaire
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Janssen
Phase 1
Multiple myeloma
#NCT06153251
Partie A, partie B cohortes 1 et 2
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
Required previous treatments
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
Multiple myeloma
#NCT06630806
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
3 or more
Required previous treatments
Car-T
Bispecific T-cell engager antibodies
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Sanofi
Phase 1
Multiple myeloma
#NCT03832127
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Radiotherapy
5 recruiting sites
Hôpital universitaire de Nantes